Novel Bacteria and Drug Discovery Research Group (NBDD), Microbes and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.
UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Int J Mol Sci. 2021 Aug 28;22(17):9360. doi: 10.3390/ijms22179360.
Biofilms formed by methicillin-resistant (MRSA) are among the most frequent causes of biomedical device-related infection, which are difficult to treat and are often persistent and recurrent. Thus, new and effective antibiofilm agents are urgently needed. In this article, we review the most relevant literature of the recent years reporting on promising anti-MRSA biofilm agents derived from the genus bacteria, and discuss the potential contribution of these newly reported antibiofilm compounds to the current strategies in preventing biofilm formation and eradicating pre-existing biofilms of the clinically important pathogen MRSA. Many efforts are evidenced to address biofilm-related infections, and some novel strategies have been developed and demonstrated encouraging results in preclinical studies. Nevertheless, more in vivo studies with appropriate biofilm models and well-designed multicenter clinical trials are needed to assess the prospects of these strategies.
耐甲氧西林金黄色葡萄球菌(MRSA)形成的生物膜是生物医学设备相关感染最常见的原因之一,这些感染难以治疗,而且往往持续存在和反复发生。因此,迫切需要新的、有效的抗生物膜剂。在本文中,我们回顾了近年来关于从 属细菌中提取的有前途的抗 MRSA 生物膜剂的最相关文献,并讨论了这些新报道的抗生物膜化合物对当前预防生物膜形成和消除临床重要病原体 MRSA 已有生物膜的策略的潜在贡献。已经有许多努力来解决与生物膜相关的感染问题,并且已经开发了一些新的策略,并在临床前研究中取得了令人鼓舞的结果。然而,需要更多的体内研究,包括使用适当的生物膜模型和精心设计的多中心临床试验,以评估这些策略的前景。